Publications
394 results found
Holman N, Barron E, Young B, et al., 2023, Comparative Incidence of Diabetes Following Hospital Admission for COVID-19 and Pneumonia: A Cohort Study., Diabetes Care, Vol: 46, Pages: 938-943
OBJECTIVE: The incidence of diabetes may be elevated following coronavirus disease 2019 (COVID-19), but it is unclear whether this is specific to severe acute respiratory syndrome coronavirus 2 infection, associated with shared risk factors for severe COVID-19 and diabetes, and/or a generic risk following illness. RESEARCH DESIGN AND METHODS: People admitted to the hospital for COVID-19 and/or pneumonia between 1 April 2020 and 31 August 2020 in England were linked with the National Diabetes Audit to identify incident diabetes after discharge up to 31 March 2021. Comparator cohorts admitted with pneumonia over the same dates in 2017, 2018, and 2019 were followed until 31 March 2018, 31 March 2019, and 31 March 2020, respectively. Poisson regression models were used to calculate adjusted diabetes incidence rates. RESULTS: Using the cohort of people discharged from the hospital following a diagnosis of COVID-19 without pneumonia in 2020 as the standard population (incidence rate 16.4 [95% CI 12.8-20.7] per 1,000 person-years), adjusting for age, sex, ethnicity, and deprivation, gave incidence rates of 19.0 (95% CI 13.8-25.6) and 16.6 (95% CI 13.3-20.4) per 1,000 person-years for those admitted for COVID-19 with pneumonia and pneumonia without COVID-19, respectively, in 2020. These rates are not significantly different from those found after hospital admission for pneumonia in 2019, 2018, and 2017, at 13.7 (95% CI 10.8-17.3), 13.8 (95% CI 10.9-17.4), and 14.2 (95% CI 10.9-18.3) per 1,000 person-years, respectively. CONCLUSIONS: Our data do not support a clear impact of COVID-19 on the incidence of diabetes compared with risks in several comparator groups, including contemporaneously assessed risks in people hospitalized with pneumonia.
Holman N, Khunti K, Wild SH, et al., 2022, Care processes in people in remission from type 2 diabetes: A cohort study using the National Diabetes Audit, DIABETIC MEDICINE, ISSN: 0742-3071
Dasgupta K, Boule N, Henson J, et al., 2022, Remission of type 2 diabetes and improved diastolic function by combining structured exercise with meal replacement and food reintroduction among young adults: the RESET for REMISSION randomised controlled trial protocol, BMJ OPEN, Vol: 12, ISSN: 2044-6055
Holman N, Wild SH, Khunti K, et al., 2022, Incidence and Characteristics of Remission of Type 2 Diabetes in England: A Cohort Study Using the National Diabetes Audit, DIABETES CARE, Vol: 45, Pages: 1151-1161, ISSN: 0149-5992
- Author Web Link
- Cite
- Citations: 4
Ruiz PLD, Chen L, Morton J, et al., 2022, Mortality trends in type 1 diabetes: a multicountry analysis of six population-based cohorts, DIABETOLOGIA, Vol: 65, Pages: 964-972, ISSN: 0012-186X
- Author Web Link
- Cite
- Citations: 5
Davis WA, Chakera A, Gregg E, et al., 2022, Temporal Trends in Renal Replacement Therapy in Community-Based People with or without Type 2 Diabetes: The Fremantle Diabetes Study, JOURNAL OF CLINICAL MEDICINE, Vol: 11
Holman N, Wild SH, Gregg EW, et al., 2022, Comparison of mortality in people with type 1 and type 2 diabetes by age of diagnosis: an incident population-based study in England and Wales, LANCET DIABETES & ENDOCRINOLOGY, Vol: 10, Pages: 95-+, ISSN: 2213-8587
- Author Web Link
- Cite
- Citations: 3
Magliano DJ, Chen L, Carstensen B, et al., 2022, Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data, LANCET DIABETES & ENDOCRINOLOGY, Vol: 10, Pages: 112-119, ISSN: 2213-8587
- Author Web Link
- Cite
- Citations: 10
Rodriguez-Flores M, Goicochea-Turcott EW, Mancillas-Adame L, et al., 2022, The utility of the Edmonton Obesity Staging System for the prediction of COVID-19 outcomes: a multi-centre study, INTERNATIONAL JOURNAL OF OBESITY, Vol: 46, Pages: 661-668, ISSN: 0307-0565
- Author Web Link
- Cite
- Citations: 5
Knudsen JS, Knudsen SS, Hulman A, et al., 2022, Changes in type 2 diabetes incidence and mortality associated with introduction of HbA1c as diagnostic option: A Danish 24-year population-based study, LANCET REGIONAL HEALTH-EUROPE, Vol: 14, ISSN: 2666-7762
- Author Web Link
- Cite
- Citations: 7
Pearson-Stuttard J, Cheng Y, Bennett J, et al., 2022, Trends in leading causes of hospitalisation among adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records, The Lancet Diabetes and Endocrinology, Vol: 10, Pages: 46-57, ISSN: 2213-8595
BackgroundDiabetes mellitus (DM) leads to a wide range of established vascular and metabolic complications which has resulted in specific prevention programmes being implemented across high-income countries. DM has been associated with increased risk of a broader set of conditions including cancers, liver disease and common infections. We aimed to examine the trends in a broad set of cause-specific hospitalisations in individuals with DM in England from 2003-2018.MethodsWe identified 309,874 individuals with DM in the Clinical Practice Research Datalink, a well described primary care database, linked to Hospital Episode Statistics inpatient data from 2003-2018. We generated a mixed prevalence and incident DM study population through serial cross sections and follow-up over time. We used a discretised Poisson regression model to estimate annual cause-specific hospitalisation rates in men and women with DM across 17 cause groupings. We generated a 1:1 age and sex matched non-DM population to compare findings. FindingsHospitalisation rates were higher for all causes in persons with DM compared to those without throughout the study period. DM itself and Ischaemic Heart Disease (IHD) were the leading causes of excess hospitalisation in 2003, but by 2018, respiratory conditions, cancers and IHD were the most common causes of excess hospitalisation across men and women. Hospitalisation rates declined in almost all traditional DM complication groupings (IHD, stroke, DM, amputations) whilst generally increasing across broader conditions (cancers, infections, respiratory conditions). These differing trends resulted in a diversification in the cause of hospitalisation, such that the traditional DM complications accounted for more than 50% of hospitalisations in 2003, but only approximately 30% in 2018. In contrast, the portion of hospitalisations that broader conditions accounted for increased including respiratory infections being attributable for 12% of hospitalisations in 2
Siegel KR, Gregg EW, Duru OK, et al., 2021, Time to start addressing (and not just describing) the social determinants of diabetes: results from the NEXT-D 2.0 network, BMJ OPEN DIABETES RESEARCH & CARE, Vol: 9
- Author Web Link
- Cite
- Citations: 1
Ali MK, Pearson-Stuttard J, Selvin E, et al., 2021, Interpreting global trends in type 2 diabetes complications and mortality, DIABETOLOGIA, Vol: 65, Pages: 3-13, ISSN: 0012-186X
- Author Web Link
- Cite
- Citations: 21
Laxy M, Zhang P, Benoit SR, et al., 2021, Trends in Total and Out-of-pocket Payments for Insulin Among Privately Insured US Adults With Diabetes From 2005 to 2018, DIABETES CARE, Vol: 44, Pages: E180-E182, ISSN: 0149-5992
- Author Web Link
- Cite
- Citations: 2
Davis K, Perez-Guzman P, Hoyer A, et al., 2021, Correction to: Association between HIV infection and hypertension: a global systematic review and meta-analysis of cross-sectional studies., BMC Medicine, Vol: 19, Pages: 228-228, ISSN: 1741-7015
Pearson-Stuttard J, Buckley J, Cicek M, et al., 2021, The changing nature of mortality and morbidity in patients with diabetes, Endocrinology and Metabolism Clinics of North America, Vol: 50, Pages: 357-368, ISSN: 0889-8529
Holman N, Knighton P, O'Keefe J, et al., 2021, Completion of annual diabetes care processes and mortality: A cohort study using the National Diabetes Audit for England and Wales, DIABETES OBESITY & METABOLISM, Vol: 23, Pages: 2728-2740, ISSN: 1462-8902
- Author Web Link
- Cite
- Citations: 10
Gregg EW, Sophiea MK, Weldegiorgis M, 2021, Diabetes and COVID-19: Population Impact 18 Months Into the Pandemic, DIABETES CARE, Vol: 44, Pages: 1916-1923, ISSN: 0149-5992
- Author Web Link
- Cite
- Citations: 22
Cicek M, Buckley J, Pearson-Stuttard J, et al., 2021, Characterising multimorbidity from type-2 diabetes: insights from clustering approaches, Endocrinology and Metabolism Clinics of North America, Vol: 50, Pages: 531-558, ISSN: 0889-8529
Patients with type-2 diabetes mellitus (T2DM) often live with and develop multiple co-occurring conditions, namely multimorbidity, with diffuse impacts on clinical care and patient quality of life. However, literature characterising T2DM-related multimorbidity patterns is limited. This review summarises the findings from the emerging literature characterising and quantifying the association of T2DM with multimorbidity clusters. Our findings reveal three dominant cluster types appearing in patients with T2DM-related multimorbidity, such as cardiometabolic precursor conditions, vascular conditions, and mental health conditions. We recommend that holistic patient care centres around early detection of other comorbidities and consideration of wider risk factors, while future research should focus on the temporality of T2DM-related multimorbidity trajectories.
Gregg EW, Moin T, 2021, New USPSTF Recommendations for Screening for Prediabetes and Type 2 Diabetes An Opportunity to Create National Momentum, JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, Vol: 326, Pages: 701-703, ISSN: 0098-7484
- Author Web Link
- Cite
- Citations: 2
Mercado C, Bullard KM, Gregg EW, et al., 2021, Differences in US Rural-Urban Trends in Diabetes ABCS, 1999-2018, DIABETES CARE, Vol: 44, Pages: 1766-1773, ISSN: 0149-5992
- Author Web Link
- Cite
- Citations: 10
Gong Q, Zhang P, Wang J, et al., 2021, Efficacy of lifestyle intervention in adults with impaired glucose tolerance with and without impaired fasting plasma glucose: A post hoc analysis of Da Qing Diabetes Prevention Outcome Study, DIABETES OBESITY & METABOLISM, Vol: 23, Pages: 2385-2394, ISSN: 1462-8902
- Author Web Link
- Cite
- Citations: 4
Wadden TA, Chao AM, Anderson H, et al., 2021, Changes in mood and health-related quality of life in Look AHEAD 6 years after termination of the lifestyle intervention, OBESITY, Vol: 29, Pages: 1294-1308, ISSN: 1930-7381
- Author Web Link
- Cite
- Citations: 3
Holman N, Knighton P, Wild SH, et al., 2021, Cohort profile: National Diabetes Audit for England and Wales, DIABETIC MEDICINE, Vol: 38, ISSN: 0742-3071
- Author Web Link
- Cite
- Citations: 7
Chan JCN, Lim L-L, Shaw JE, et al., 2021, Data on diabetes-specific distress are needed to improve the quality of diabetes care reply, LANCET, Vol: 397, Pages: 2150-2150, ISSN: 0140-6736
Mora-Diaz JC, Pineyro PE, Rauh R, et al., 2021, Porcine Hemagglutinating Encephalomyelitis Virus Infection In Vivo and Ex Vivo, JOURNAL OF VIROLOGY, Vol: 95, ISSN: 0022-538X
- Author Web Link
- Cite
- Citations: 11
Davis K, Perez Guzman P, Hoyer A, et al., 2021, Association between HIV infection and hypertension: a global systematic review and meta-analysis of cross-sectional studies, BMC Medicine, Vol: 19, ISSN: 1741-7015
Background:Improved access to effective antiretroviral therapy has meant that people living with HIV (PLHIV) are surviving to older ages. However, PLHIV may be ageing differently to HIV-negative individuals, with dissimilar burdens of non-communicable diseases, such as hypertension. While some observational studies have reported a higher risk of prevalent hypertension among PLHIV compared to HIV-negative individuals, others have found a reduced burden. To clarify the relationship between HIV and hypertension, we identified observational studies and pooled their results to assess whether there is a difference in hypertension risk by HIV status.Methods:We performed a global systematic review and meta-analysis of published cross-sectional studies that examined hypertension risk by HIV status among adults aged > 15 (PROSPERO: CRD42019151359). We searched MEDLINE, EMBASE, Global Health and Cochrane CENTRAL to August 23, 2020, and checked reference lists of included articles. Our main outcome was the risk ratio for prevalent hypertension in PLHIV compared to HIV-negative individuals. Summary estimates were pooled with a random effects model and meta-regression explored whether any difference was associated with study-level factors.Results:Of 21,527 identified studies, 59 were eligible (11,101,581 participants). Crude global hypertension risk was lower among PLHIV than HIV-negative individuals (risk ratio 0.90, 95% CI 0.85–0.96), although heterogeneity between studies was high (I2 = 97%, p < 0.0001). The relationship varied by continent, with risk higher among PLHIV in North America (1.12, 1.02–1.23) and lower among PLHIV in Africa (0.75, 0.68–0.83) and Asia (0.77, 0.63–0.95). Meta-regression revealed strong evidence of a difference in risk ratios when comparing North American and European studies to African ones (North America 1.45, 1.21–1.74; Europe 1.20, 1.03–1.40).Conclusions:Our findings suggest that the r
Shao H, Laxy M, Benoit SR, et al., 2021, Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among US Adults With Large-Employer Private Health Insurance From 2005 to 2018, DIABETES CARE, Vol: 44, Pages: 925-934, ISSN: 0149-5992
- Author Web Link
- Cite
- Citations: 4
Bardenheier BH, Wu W-C, Zullo AR, et al., 2021, Progression to diabetes by baseline glycemic status among middle-aged and older adults in the United States, 2006-2014, DIABETES RESEARCH AND CLINICAL PRACTICE, Vol: 174, ISSN: 0168-8227
- Author Web Link
- Cite
- Citations: 5
Magliano DJ, Chen L, Islam RM, et al., 2021, Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings, LANCET DIABETES & ENDOCRINOLOGY, Vol: 9, Pages: 203-211, ISSN: 2213-8587
- Author Web Link
- Cite
- Citations: 35
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.